Zoledronic acid ups bone density but doesn't reduce fractures

Zoledronic acid (Zometa®, Zomera®, Reclast®, Aclasta®), like other bisphosphonate drugs, slows bone resorption by binding to bone and inducing apoptosis (killing) osteoclasts, the bone cells that clear old bone to make room for new. A study just published in JAMA Internal Medicine adds to the evidence that this strategy, while improving bone mineral density, may not reduce and may even worsen fractures.